BBI Solutions & Dr C. Sturgeon Consider International Standards For Cancer Biomarkers
Dr Catharine Sturgeon will be presenting her case for an international effort to align manufacturer’s assays for CA125, CA19-9 and other mucinous markers in a webinar. Organised by BBI Solutions, a leading manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market, the webinar will cover benefits of tumour marker standardisation and discuss how tumour marker standardisation can be improved.
Dr Sturgeon is a Consultant Clinical Scientist and Director of the UK NEQAS unit at the Royal Infirmary of Edinburgh. She has a particular interest in tumour markers and has worked to encourage their appropriate use through implementation of practice guidelines, such as those of the European Group on Tumour Markers and the National Academy of Clinical Biochemistry. Catharine has a long-standing interest in improving both analytical quality and clinical interpretation of laboratory tests. She has been actively involved in several standardisation projects, including those of the IFCC Working Groups on hCG and growth hormone.
International Standards (IS) and International Reference Preparations help to improve between-laboratory comparability of immunoassay results and can also enable better understanding of what is being measured. The ‘good agreement’ between results observed for AFP and PSA markers reflects the availability of appropriately constituted International Standards for these important tumour markers. Those for hCG are also contributing to optimal design of the next generation of hCG immunoassays. However, there are, as yet, no International Standards for CA125, CA19-9 and other mucinous markers for which between-method agreement is poor.
In the webinar, Dr. Catharine Sturgeon will consider why this is the case and what collaborative international initiatives are required to fill the gap.
The webinar titled: Standardisation of serum tumour markers – optional extra or essential? Is on Tuesday 4th April 2017, 3pm BST. Spaces are limited so reserve your place today by following this link: www.bbisolutions.com/webinar.
- ends –
About
BBI Solutions is a leading manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market. BBI has grown from a small specialist company to a global business with manufacturing sites spanning three countries.
Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.
BBI Solutions offer contract development and manufacturing services with a core focus on gold conjugation and lateral flow test manufacture.
BBI Solutions is part of the BBI Group.
www.bbisolutions.com
Media Contact
Laura Baker
T: +44 (0) 2920 747232
E: LauraBaker@bbisolutions.com
Dr Sturgeon is a Consultant Clinical Scientist and Director of the UK NEQAS unit at the Royal Infirmary of Edinburgh. She has a particular interest in tumour markers and has worked to encourage their appropriate use through implementation of practice guidelines, such as those of the European Group on Tumour Markers and the National Academy of Clinical Biochemistry. Catharine has a long-standing interest in improving both analytical quality and clinical interpretation of laboratory tests. She has been actively involved in several standardisation projects, including those of the IFCC Working Groups on hCG and growth hormone.
International Standards (IS) and International Reference Preparations help to improve between-laboratory comparability of immunoassay results and can also enable better understanding of what is being measured. The ‘good agreement’ between results observed for AFP and PSA markers reflects the availability of appropriately constituted International Standards for these important tumour markers. Those for hCG are also contributing to optimal design of the next generation of hCG immunoassays. However, there are, as yet, no International Standards for CA125, CA19-9 and other mucinous markers for which between-method agreement is poor.
In the webinar, Dr. Catharine Sturgeon will consider why this is the case and what collaborative international initiatives are required to fill the gap.
The webinar titled: Standardisation of serum tumour markers – optional extra or essential? Is on Tuesday 4th April 2017, 3pm BST. Spaces are limited so reserve your place today by following this link: www.bbisolutions.com/webinar.
- ends –
About
BBI Solutions is a leading manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market. BBI has grown from a small specialist company to a global business with manufacturing sites spanning three countries.
Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.
BBI Solutions offer contract development and manufacturing services with a core focus on gold conjugation and lateral flow test manufacture.
BBI Solutions is part of the BBI Group.
www.bbisolutions.com
Media Contact
Laura Baker
T: +44 (0) 2920 747232
E: LauraBaker@bbisolutions.com